Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Targeting nuclear export and Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) signalling in myelofibrosis: A novel combinatorial strategy that impacts intrinsic and microenvironment-related pathways.
Journal: British journal of haematology
Published: May 06, 2026
Single agent selinexor is active in patients with myelofibrosis refractory or intolerant to JAK inhibitors.
Journal: Blood cancer journal
Published: April 30, 2026
First-in-Human Phase I Study of KPT-9274, a First-in-Class Dual Inhibitor of PAK4 and NAMPT, in Patients with Advanced Solid Malignancies.
Journal: Targeted oncology
Published: October 22, 2025
An evaluation of selinexor as a maintenance therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma.
Journal: Expert review of anticancer therapy
Published: June 23, 2025
Modulation of anti-tumour immunity by XPO1 inhibitors.
Journal: Exploration of targeted anti-tumor therapy
Published: January 13, 2025
Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study.
Journal: Gynecologic oncology
Published: May 13, 2024
The Functional Transcriptomic Landscape Informs Therapeutic Strategies in Multiple Myeloma.
Journal: Cancer research
Published: March 22, 2024
Impacting T-cell fitness in multiple myeloma: potential roles for selinexor and XPO1 inhibitors.
Journal: Frontiers in immunology
Published: August 09, 2023
Preclinical activity of selinexor in combination with eribulin in uterine leiomyosarcoma.
Journal: Experimental hematology & oncology
Published: June 23, 2023
Last Updated: 09/26/2026